Takeda

News

Takeda's first-in-class narcolepsy drug claims FDA approval

Takeda's orexin agonist Orzeyful is the first drug approved in the US that can treat the "full range" of narcolepsy type 1 symptoms, says the FDA.

News

Takeda gets first OK for orexin narcolepsy drug, in China

China has become the first country to approve Takeda's first-in-class orexin agonist, oveporexton, for the sleep disorder narcolepsy.

News

Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest

New data with Takeda's TYK2 inhibitor zasocitinib suggest it is significantly more effective than BMS's Sotyktu in the treatment of psoriasis.

Oncology

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...

Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.

Digital

How pharma and start-ups are working together for AI success

At the PharmStars Pharmtech Innovation Summit in Boston, start-up founders and pharma executives shared the stage to share lessons on AI deployment.

News

Jury finds Takeda liable for $885m in pay-for-delay lawsuit

Takeda is on the hook for $885m damages – which could rise to $2.5bn – in a suit claiming it paid a rival to delay the launch of a generic competitor.

Takeda's first-in-class narcolepsy drug claims FDA approval

Takeda gets first OK for orexin narcolepsy drug, in China

Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...

How pharma and start-ups are working together for AI success

Jury finds Takeda liable for $885m in pay-for-delay lawsuit

TransThera's resistant biliary cancer drug cleared in China

Discover a new era of healthcare panel engagement: Grounded ...

Takeda

Editor's Picks